Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Chemomab Therapeutics (Nasdaq: CMMB) will have Dr. Adi Mor, the CEO, present at the Aegis Virtual Conference on May 7, 2024, discussing innovative therapeutics for fibro-inflammatory diseases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chemomab Therapeutics (Nasdaq: CMMB) will have Dr. Adi Mor, the CEO, present at the Aegis Virtual Conference on May 7, 2024, discussing innovative therapeutics for fibro-inflammatory diseases. The presentation will be webcast live, offering further insights into the company's endeavors.
Details
News Market Reaction – CMMB
The recorded move for CMMB in the trading session of this news was +1.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast live. The registration link to access the live presentation is included below and is also available at the Events section of the Chemomab website.
Chemomab Presentation at 2024 Aegis Virtual Conference
| Date: | May 7, 2024 |
| Time: | 9:00 am ET |
| Venue: | Virtual |
| Format: | Live webcast presentation |
| Registration: | https://us02web.zoom.us/meeting/register/tZMkd-2trzIsHNTrU4RNyTw2dYX2Pqs_t-o8 |
| Information: | info@aegiscap.com |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information about Chemomab, visit chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.